SRR33346941
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.650
- CHOLESTEROL_HOMEOSTASIS+0.530
- TGF_BETA_SIGNALING+0.530
- TNFA_SIGNALING_VIA_NFKB+0.510
- ANDROGEN_RESPONSE+0.480
- PROTEIN_SECRETION+0.470
- HYPOXIA+0.450
- INTERFERON_GAMMA_RESPONSE+0.420
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.400
- MTORC1_SIGNALING+0.320
Top 10 suppressed
- E2F_TARGETS-0.480
- MYC_TARGETS_V2-0.450
- G2M_CHECKPOINT-0.370
- DNA_REPAIR-0.270
- SPERMATOGENESIS-0.210
- ALLOGRAFT_REJECTION-0.140
- APICAL_SURFACE-0.120
- BILE_ACID_METABOLISM-0.100
- MYC_TARGETS_V1-0.080
- HEDGEHOG_SIGNALING-0.070
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_49852ZBH | pilocytic astrocytoma | — | 0.881 |
| 2 | TCGA-CN-6998-01A-23R-2016-07 | — | — | 0.863 |
| 3 | BS_FJWZ3M7V | low-grade glioma | — | 0.837 |
| 4 | BS_42Y3YANN | pilocytic astrocytoma | — | 0.832 |
| 5 | BS_SDZY6RZ3 | pilocytic astrocytoma | — | 0.825 |
| 6 | 9A593453-3B4C-4557-84BF-E9E902AA0F3F | — | — | 0.822 |
| 7 | BS_4A45GGSW | pilocytic astrocytoma | — | 0.821 |
| 8 | DRR168524 | — | — | 0.819 |
| 9 | 6C8488D3-6826-4156-9BD9-A12D8F35B72B | — | — | 0.810 |
| 10 | s_150324_7b | EPN | Posterior Fossa EPN | 0.809 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 36 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.650 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.530 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.530 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.510 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.480 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.470 | Remibrutinib | — uncovered |
| HYPOXIA | 0.450 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.420 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.400 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.320 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.320 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.300 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.300 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.300 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.290 | Inavolisib | — uncovered |
| APOPTOSIS | 0.260 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.260 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.250 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.230 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.220 | Inavolisib | — uncovered |